LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
Year: 2023
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Peter MacCallum Cancer Centre, Samsung Medical Center, Gdańsk Medical University, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Asan Medical Center, Seoul National University, Seoul National University Bundang Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, National Cancer Center Hospital, Chinese Academy of Sciences, European Institute of Oncology, Azienda Ospedaliera San Camillo-Forlanini, Dnipro State Medical University, F. Hoffmann-La Roche AG, Roche (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, International Association for the Study of Lung Cancer, F. Hoffmann-La Roche, Seoul National University Bundang Hospital, BeiGene, Yuhan, Chinese Academy of Sciences, Seoul National University, Southern Medical University, Guangdong Provincial People's Hospital, Genentech, Samsung, Cancer Council Victoria, Centro de Instrumentación Científico-Técnica, Universidad de Jaén
OpenAlex ID: W4387809549